- Zacks•last month
Prima BioMed Ltd (PBMD) announced initial data from a phase IIb chemo-immunotherapy study on IMP321 for the treatment of metastatic breast cancer.
- Benzinga•last monthPrima BioMed Announces First Safety, Pharmacokinetics, Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321 -
Prima BioMed Ltd (NASDAQ: PBMD ) is pleased to announce initial safety data from the first cohort of patients in its Phase IIb AIPAC chemo-immunotherapy clinical study of Prima's lead compound, IMP321. ...
|52wk Range||0.04 - 0.07|
|Day's Range||0.04 - 0.04|
|Avg Vol (3m)||1,219,218|
As of 2:10 AM EDT. Market closed.